Chest. 1990 Jun;97(6):1299-306. doi: 10.1378/chest.97.6.1299.
To determine the efficacy of nedocromil sodium in adult asthma patients using bronchodilators alone to control their disease, a consecutive sample of 127 patients with long-term asthma was studied for 16 weeks. The patients were maintained on sustained release theophylline preparations (SRT) and inhaled and oral beta-adrenergic bronchodilators (beta 2). One hundred sixteen patients (90 percent) completed the study; one placebo-treated patient withdrew owing to throat irritation and wheezing. Nedocromil sodium provided an additional benefit to adult patients receiving SRT and inhaled beta 2-agonists. With the exception of night-time asthma, nedocromil sodium maintained this improvement for the final 12 weeks of the study despite a reduction in concomitant bronchodilator therapy.
为确定奈多罗米钠对仅使用支气管扩张剂控制病情的成年哮喘患者的疗效,对连续抽样的127例长期哮喘患者进行了为期16周的研究。患者维持使用缓释茶碱制剂(SRT)以及吸入和口服β-肾上腺素能支气管扩张剂(β2)。116例患者(90%)完成了研究;1例接受安慰剂治疗的患者因咽喉刺激和喘息而退出。奈多罗米钠为接受SRT和吸入β2-激动剂的成年患者带来了额外益处。除夜间哮喘外,在研究的最后12周,尽管同时使用的支气管扩张剂治疗有所减少,但奈多罗米钠仍维持了这种改善效果。